[go: up one dir, main page]

MX2022012447A - Vacuna inactivada contra el virus sars-cov-2. - Google Patents

Vacuna inactivada contra el virus sars-cov-2.

Info

Publication number
MX2022012447A
MX2022012447A MX2022012447A MX2022012447A MX2022012447A MX 2022012447 A MX2022012447 A MX 2022012447A MX 2022012447 A MX2022012447 A MX 2022012447A MX 2022012447 A MX2022012447 A MX 2022012447A MX 2022012447 A MX2022012447 A MX 2022012447A
Authority
MX
Mexico
Prior art keywords
cov
sars
virus
vaccine against
inactivated vaccine
Prior art date
Application number
MX2022012447A
Other languages
English (en)
Inventor
Robert Schlegl
Andreas Meinke
Jürgen Heindl-Wruss
Michael Möhlen
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/020313 external-priority patent/WO2021178318A1/en
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Priority claimed from PCT/EP2021/058974 external-priority patent/WO2021204825A2/en
Publication of MX2022012447A publication Critical patent/MX2022012447A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Aquí se describen vacunas contra el SARS-CoV-2 y composiciones y métodos para producir y administrar dichas vacunas a sujetos que las necesitan.
MX2022012447A 2020-04-06 2021-04-06 Vacuna inactivada contra el virus sars-cov-2. MX2022012447A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20168324 2020-04-06
EP20202118 2020-10-15
EP20211853 2020-12-04
EP21154647 2021-02-01
PCT/US2021/020313 WO2021178318A1 (en) 2020-03-01 2021-03-01 Coronavirus vaccines comprising a tlr9 agonist
EP21160913 2021-03-05
PCT/EP2021/058974 WO2021204825A2 (en) 2020-04-06 2021-04-06 INACTIVATED SARS-CoV-2 VIRUS VACCINE

Publications (1)

Publication Number Publication Date
MX2022012447A true MX2022012447A (es) 2022-10-27

Family

ID=79566178

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012447A MX2022012447A (es) 2020-04-06 2021-04-06 Vacuna inactivada contra el virus sars-cov-2.

Country Status (15)

Country Link
US (1) US20240293531A1 (es)
EP (1) EP3955959A2 (es)
JP (1) JP2023520521A (es)
KR (1) KR20220164500A (es)
CN (1) CN115768469A (es)
AU (1) AU2021253605A1 (es)
BR (1) BR112022020100A2 (es)
CA (1) CA3168784A1 (es)
CL (1) CL2022002365A1 (es)
CO (1) CO2022013715A2 (es)
EC (1) ECSP22072590A (es)
IL (1) IL296072A (es)
MX (1) MX2022012447A (es)
PH (1) PH12022552239A1 (es)
ZA (1) ZA202209826B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240035101A1 (en) * 2022-08-01 2024-02-01 Wisconsin Alumni Research Foundation Method for selecting antigenic viral sequences for vaccines and therapeutics

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
CN107174658B (zh) * 2017-04-29 2020-11-27 安徽智飞龙科马生物制药有限公司 人用水痘病毒灭活疫苗及其制备方法

Also Published As

Publication number Publication date
JP2023520521A (ja) 2023-05-17
CL2022002365A1 (es) 2023-02-03
PH12022552239A1 (en) 2024-02-12
US20240293531A1 (en) 2024-09-05
CN115768469A (zh) 2023-03-07
KR20220164500A (ko) 2022-12-13
IL296072A (en) 2022-11-01
CA3168784A1 (en) 2021-10-14
ECSP22072590A (es) 2022-10-31
BR112022020100A2 (pt) 2022-11-29
AU2021253605A1 (en) 2022-10-06
EP3955959A2 (en) 2022-02-23
ZA202209826B (en) 2023-05-31
CO2022013715A2 (es) 2022-12-30

Similar Documents

Publication Publication Date Title
WO2021204825A3 (en) INACTIVATED SARS-CoV-2 VIRUS VACCINE
ECSP22072586A (es) VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG
EP4218807A3 (en) Zika virus vaccine
MX2018014573A (es) Vacuna contra el virus del zika.
MX2021001762A (es) Metodo y composicion para estimular la respuesta inmunitaria.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
MX2020011712A (es) Vacunas de nanoparticulas multivalentes contra la influenza.
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
PE20151588A1 (es) Vacuna contra el virus del dengue
MX2020003756A (es) Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
MX2022010781A (es) Vacuna contra el virus sars-cov-2 con adyuvante cpg.
PH12016502529A1 (en) Influenza vaccine nasal vaccination system
BR112022020298A2 (pt) Vacinas, adjuvantes e métodos para gerar uma resposta imune
CL2017001595A1 (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
MX2022012447A (es) Vacuna inactivada contra el virus sars-cov-2.
CO2022016537A2 (es) Vacuna inactivada para sars-cov-2 y preparación de la misma
EA202190914A1 (ru) Иммуногенные композиции
AR115070A1 (es) Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso
UY39714A (es) Composiciones de vacuna de staphylococcus aureus
AR121752A1 (es) VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2